Adding L-Carnitine to Clomiphene Citrate for Induction of Ovulation in Women With Polycystic Ovary Syndrome

Status

Completed

Phases

Phase 4

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT03630341

Enrollment

150

Registered

2018-08-14

Start date

2016-02-01

Completion date

2018-05-31

Last updated

2018-08-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Polycystic Ovary Syndrome

Brief summary

Polycystic ovary syndrome is one of the most common endocrine disorders, affecting about 6-10% of women in their reproductive age. Anovulation and hyperandrogenism are often present together with hyperinsulinaemia and insulin resistance

Interventions

DRUGClomiphene Citrate 50mg

oral 50 mg tablets

DRUGL-carnitine

1000 mg oral tablet

DRUGPlacebo Oral Tablet

oral tablets identical to L-carnitine

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender

FEMALE

Age

18 Years to 35 Years

Healthy volunteers

Inclusion criteria

* Primary or secondary infertility. * Normal Hysterosalpingo-graphy * Normal Semen analysis of the husband.

Exclusion criteria

* Patient's refusal. * Male factors of infertility and/or abnormal Hysterosalpingo-graphy * Hyperprolactinemia (prolactin ≥ 22 ng/dl). * FSH on day 3 \> 15 mIU/mL. * Gross ovarian pathology diagnosed by ultrasound.

Design outcomes

Primary

Measure	Time frame	Description
clinical pregnancy rate	1 month	visible intra-uterine gestational sac, with a positive fetal heart beat, viewed during a transvaginal ultrasound (when the b-hCG concentration was more than 1500 IU/l)

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026